Sign In
Buy JAZZ
$252.86
-5.52 (-2.14%)
At Close: Jul 31, 2026
Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates
06:50pm, Tuesday, 25'th Feb 2025
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.60 per share, beating the Zacks Consensus Estimate of $5.79 per share. This compares to earnings of $5.02 per share a year ago.
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
04:05pm, Tuesday, 25'th Feb 2025
– Record total revenues of $4.1 billion in 2024 and $1.1 billion in 4Q24 –– Xywav ® and Epidiolex ® revenues grew 16% and 15% year-over-year, respectively, in 2024 –– Oncology revenues gre
Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference
04:15pm, Thursday, 20'th Feb 2025
DUBLIN , Feb. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in TD Cowen's 45th Annual Health Care Conference. Company management w
Jazz (JAZZ) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
10:20am, Thursday, 20'th Feb 2025
Get a deeper insight into the potential performance of Jazz (JAZZ) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some
Jazz (JAZZ) Surges 5.2%: Is This an Indication of Further Gains?
10:26am, Wednesday, 12'th Feb 2025
Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
04:15pm, Tuesday, 11'th Feb 2025
DUBLIN , Feb. 11, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 full year and fourth quarter financial results on Tuesday, February 25, 2025
Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again
01:11pm, Wednesday, 05'th Feb 2025
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Biotech Stocks With Notable Insider Buying
12:29pm, Wednesday, 22'nd Jan 2025
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-c
3 Oversold Biotech Names
12:56pm, Monday, 13'th Jan 2025
High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens t
Jazz Pharmaceuticals: Should Sing A Better Tune In 2025
12:53pm, Monday, 23'rd Dec 2024
Jazz Pharmaceuticals' stock moved nicely higher post-3Q24 report and FDA approval of zanidatamab, despite challenges in its narcolepsy franchise from Avadel's Lumryz. Jazz's neuroscience franchise fac
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
04:15pm, Tuesday, 17'th Dec 2024
DUBLIN , Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare Confer
Jazz Pharmaceuticals Announces CEO Succession Plan
04:05pm, Monday, 16'th Dec 2024
Bruce Cozadd, Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the Board Mr. Cozadd Has Led Growth of Company from Fo
5 High ROE Stocks to Buy as Volatility Weighs on Markets
10:26am, Wednesday, 11'th Dec 2024
DIS, LDOS, RF, FTNT and JAZZ are some of the stocks with high ROE to profit from as intense volatility spooks markets.
Data from nine abstracts to be presented, including first data from the EpiCom Trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, which suggests improv
Ziihera, the first and only FDA-approved dual HER2-targeted bispecific antibody for HER2+ (IHC 3+) BTC, is now commercially available in the United States For U.S. media and investors only DUBLIN , De
